Precision Medicine Market Summary
- The Precision Medicine market size is estimated at USD 110 billion in 2025 and is projected to reach USD 300 billion by 2034. Growth is anchored in the rising burden of cancer and chronic disease, the falling cost and expanding use of genomic sequencing, and the rapid growth of targeted therapies and companion diagnostics.
- The global Precision Medicine market is growing at a CAGR of 11.8% during the forecast period from 2026 to 2034.
- By technology, the genomics and next-generation sequencing segment dominated the Precision Medicine market with a 34% share in 2025.
- By application, the oncology segment dominated the Precision Medicine market with a share of 40% in 2025.
- By end-user, the hospitals and clinics segment dominated the Precision Medicine market with a share of 40% in 2025.
- North America dominated the global Precision Medicine market revenue with a share of 48% in 2025, representing the highest regional market share globally.
Precision medicine is an approach to disease prevention, diagnosis, and treatment that tailors medical decisions to the individual characteristics of each patient, particularly their genetic, molecular, and biomarker profile. The market encompasses the technologies, diagnostics, and therapies that enable this approach, including genomics and next-generation sequencing, bioinformatics and data analytics, companion diagnostics, pharmacogenomics, and targeted and biomarker-guided therapeutics. Enabling technologies and diagnostics are supplied by companies such as Illumina, Thermo Fisher Scientific, QIAGEN, Roche through Foundation Medicine, Guardant Health, and Tempus AI, while targeted therapies are developed by pharmaceutical companies including Roche, Novartis, Pfizer, AstraZeneca, and Merck. Precision medicine is applied across oncology, neurology, immunology, infectious diseases, cardiovascular, respiratory, and rare diseases, delivered in hospitals, clinical and reference laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. Over the past decade, the field has advanced with the dramatic fall in sequencing costs, the proliferation of targeted therapies and companion diagnostics, the growth of liquid biopsy, and the application of artificial intelligence and large-scale data to drug discovery and clinical decision-making. Driven by the rising burden of cancer and chronic disease, expanding genomic testing, and the growth of targeted therapy, precision medicine is one of the largest and fastest-growing areas of healthcare.
Precision Medicine Market Key Growth Drivers
- The rising global burden of cancer and chronic disease is expanding demand for precision diagnostics and targeted therapies.
- The dramatic fall in the cost of genomic sequencing and the expansion of next-generation sequencing are broadening access to molecular profiling.
- The rapid growth of targeted therapies and companion diagnostics is driving biomarker-guided treatment across oncology and other areas.
- The application of artificial intelligence, big data, and bioinformatics to drug discovery and clinical decision-making is accelerating precision medicine.
- The growth of liquid biopsy and minimally invasive molecular testing is expanding precision diagnostics.
- Government and institutional genomics and precision medicine initiatives are expanding infrastructure, data, and adoption.
- The convergence of rising disease burden, expanding genomic testing, and targeted therapy is expected to sustain strong growth in the global Precision Medicine market through 2034.
Key Companies in Precision Medicine Market
The competitive landscape is led by the following active developers and providers of precision medicine technologies, diagnostics, and therapeutics:
- F. Hoffmann-La Roche Ltd
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Novartis AG
- Pfizer Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Guardant Health, Inc.
- Tempus AI, Inc., and others
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies relevant to the market assessment.
Precision Medicine Market Size
The following snapshot summarizes the principal report metrics for the Precision Medicine market.
|
Report Metrics |
Details |
|
2025 Market Size |
USD 110 billion |
|
2034 Projected Market Size |
USD 300 billion |
|
Growth Rate (2026-2034) |
11.8% CAGR |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia-Pacific |
|
Market Structure |
Fragmented |
All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.
Factors Contributing to the Growth of the Precision Medicine Market
Precision Medicine Market Drivers
- Rising Burden of Cancer and Chronic Disease: The escalating global burden of cancer and chronic disease is the foundational driver of the precision medicine market. According to the International Agency for Research on Cancer, approximately 20 million new cancer cases were diagnosed in 2022, with cases projected to reach 35 million by 2050, and the burden of chronic and genetically influenced diseases continues to rise worldwide. Precision medicine is central to modern oncology, where molecular profiling and biomarker testing guide the selection of targeted therapies and immunotherapies, and it is expanding into neurology, immunology, cardiovascular disease, and rare genetic disorders. The rising number of patients requiring molecular diagnosis and tailored treatment directly expands demand for precision diagnostics and therapeutics. As the burden of cancer and chronic disease continues to rise and precision approaches become standard across more conditions, demand for precision medicine continues to grow, reinforcing sustained market growth throughout the forecast period.
- Falling Cost and Expanding Use of Genomic Sequencing: The dramatic fall in the cost of genomic sequencing and the expanding use of next-generation sequencing are powerful drivers of the precision medicine market. The cost of sequencing a human genome has fallen by orders of magnitude over the past two decades, and continued advances from companies such as Illumina and Thermo Fisher Scientific have made comprehensive molecular profiling increasingly affordable and accessible. Next-generation sequencing enables comprehensive genomic profiling, companion diagnostic testing, and the identification of actionable biomarkers from tissue and blood, and its adoption continues to expand across clinical and research settings. Falling costs, rising throughput, and broader clinical adoption expand the use of molecular profiling that underpins precision medicine. As sequencing becomes cheaper and more widely used, expanding genomic testing is expected to be a leading driver of precision medicine market growth across the forecast period.
- Growth of Targeted Therapies and Companion Diagnostics: The rapid growth of targeted therapies and companion diagnostics is a defining driver of the precision medicine market. The expansion of targeted therapies, including those directed at specific genetic alterations in cancer and other diseases, has made biomarker testing essential to treatment selection, and companion diagnostics identify the patients most likely to benefit from specific therapies. The Food and Drug Administration has approved a growing number of targeted therapies with companion diagnostics, including next-generation sequencing-based and liquid biopsy companion diagnostics from Roche through Foundation Medicine, Guardant Health, and others, across oncology and beyond. The co-development of drugs and diagnostics by pharmaceutical and diagnostic companies continues to expand the precision medicine ecosystem. As targeted therapies and companion diagnostics continue to proliferate, this growth is expected to be a leading driver of precision medicine market growth across the forecast period.
- Application of Artificial Intelligence and Big Data: The application of artificial intelligence, big data, and bioinformatics is a significant driver of the precision medicine market. The integration of genomic, clinical, imaging, and real-world data, analyzed with artificial intelligence and machine learning, is accelerating biomarker discovery, drug development, and clinical decision-making, and companies such as Tempus AI and Roche through Foundation Medicine build large multimodal datasets and analytics platforms. Strategic alliances between pharmaceutical companies and technology and data companies are speeding precision drug discovery and the identification of patient subgroups. Bioinformatics and data analytics are essential to interpreting the large and complex data generated by genomic and molecular testing. These capabilities improve the efficiency and precision of diagnosis and treatment. As artificial intelligence and big data continue to transform drug discovery and clinical care, their application is expected to be a significant driver of precision medicine market growth across the forecast period.
- Growth of Liquid Biopsy and Minimally Invasive Testing: The rapid growth of liquid biopsy and minimally invasive molecular testing is a substantial driver of the precision medicine market. Liquid biopsy, which detects tumor-derived nucleic acids and other analytes in blood, enables molecular profiling when tissue is insufficient or inaccessible, faster results, and monitoring of treatment response, resistance, and minimal residual disease. Blood-based companion diagnostics and comprehensive genomic profiling from companies such as Guardant Health, Roche through Foundation Medicine, and Natera are approved and expanding across oncology, and liquid biopsy is being explored for early detection and other applications. Minimally invasive testing broadens access to molecular profiling and supports longitudinal monitoring. As liquid biopsy and minimally invasive testing continue to grow and expand into new applications, they are expected to be an important driver of precision medicine market growth across the forecast period.
- Government and Institutional Genomics Initiatives: Government and institutional genomics and precision medicine initiatives are a substantial driver of the market. Large-scale national and institutional programs, including population genomics and precision medicine initiatives in the United States, the United Kingdom, and other countries, are building genomic infrastructure, datasets, and clinical adoption that advance precision medicine. These programs support research, biomarker discovery, and the integration of genomics into clinical care, and public funding and policy increasingly support precision approaches. Investment in genomic infrastructure, data sharing, and clinical implementation expands the foundation for precision medicine. As governments and institutions continue to invest in genomics and precision medicine, these initiatives are expected to be an important driver of market growth across the forecast period, particularly in building infrastructure and expanding adoption.
Precision Medicine Market Restraints
Despite strong momentum, the Precision Medicine market faces material constraints. The high cost of genomic profiling, targeted therapies, and companion diagnostics strains healthcare budgets and payers and limits access, particularly in resource-limited settings and for comprehensive testing. Reimbursement for molecular profiling and precision diagnostics varies across payers and countries and can be restrictive, limiting adoption of guideline-recommended testing. The interpretation of complex genomic and molecular data requires specialized expertise and bioinformatics capacity, and a shortage of trained specialists can constrain capacity. Data privacy, security, and governance concerns around large-scale genomic and health data raise significant regulatory and ethical considerations. The integration of genomic data into clinical workflows and electronic health records remains challenging, and evidence of clinical utility and health-economic value is still developing for some applications. Rigorous and evolving regulatory requirements for diagnostics, companion diagnostics, and laboratory-developed tests, including Food and Drug Administration oversight and the European In Vitro Diagnostic Regulation, add cost and complexity. Finally, uneven infrastructure, limited access to targeted therapies, and affordability constraints in emerging markets can restrict adoption across parts of the forecast period.
Precision Medicine Market Segment Analysis
The Precision Medicine Market is segmented by technology (genomics and next-generation sequencing, bioinformatics and data analytics, companion diagnostics, pharmacogenomics, drug discovery and development, others), application (oncology, neurology, immunology, infectious diseases, cardiovascular, respiratory, others), end-user (hospitals and clinics, diagnostic and clinical laboratories, pharmaceutical and biotechnology companies, academic and research institutes, others), and geography (North America, Europe, Asia-Pacific, Rest of World).
By Technology
Dominant Subsegment: Genomics and Next-Generation Sequencing.
The genomics and next-generation sequencing segment accounted for 34% of the Precision Medicine market in 2025. Genomics and next-generation sequencing dominate because comprehensive molecular profiling is the foundation of precision medicine, enabling the identification of actionable genetic alterations and biomarkers that guide targeted therapy, companion diagnostics, and clinical decision-making. Next-generation sequencing platforms from Illumina and Thermo Fisher Scientific, and comprehensive genomic profiling from Roche through Foundation Medicine and others, underpin the large and growing volume of molecular testing, and falling sequencing costs continue to expand adoption. Companion diagnostics represent a large and rapidly growing segment tied directly to targeted therapy approvals, and bioinformatics and data analytics are essential and fast-growing, interpreting the complex data generated by genomic testing and powering artificial intelligence applications. Pharmacogenomics, drug discovery and development technologies, and other technologies add further demand. Nonetheless, the foundational role, breadth, and expanding adoption of genomics and next-generation sequencing secure the leadership of this segment across the forecast period, with bioinformatics and companion diagnostics growing strongly.
By Application
Dominant Subsegment: Oncology.
The oncology segment accounted for 40% of the Precision Medicine market in 2025. Oncology dominates because cancer is the leading application of precision medicine, where molecular profiling and biomarker testing are central to the selection of targeted therapies and immunotherapies and are increasingly standard of care. Comprehensive genomic profiling, companion diagnostics, and liquid biopsy guide treatment across a wide and growing range of cancers, and the large and expanding portfolio of targeted and biomarker-guided cancer therapies drives extensive molecular testing. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, expanding the population requiring molecular diagnosis and tailored treatment. Neurology, immunology, infectious diseases, cardiovascular disease, respiratory disease, and rare diseases represent growing applications as precision approaches expand beyond oncology, supported by pharmacogenomics and biomarker testing. Nonetheless, the centrality of molecular profiling and targeted therapy in cancer treatment, and the scale of the oncology market, secure the leadership of the oncology segment across the forecast period, with other applications growing.
By End-User
Dominant Subsegment: Hospitals and Clinics.
The hospitals and clinics segment accounted for 40% of the Precision Medicine market in 2025. Hospitals and clinics dominate because they are the primary settings where precision medicine is delivered, where clinicians order molecular profiling and companion diagnostic testing, interpret results, and administer targeted and biomarker-guided therapies. The concentration of cancer treatment, complex diagnosis, and specialty care in hospitals and clinics drives the largest share of precision medicine activity, and hospitals increasingly integrate genomic testing and molecular tumor boards into clinical care. Diagnostic and clinical laboratories represent a large and growing end user, performing high-volume and specialized molecular profiling, next-generation sequencing, and liquid biopsy on a centralized basis, including reference and specialty laboratories. Pharmaceutical and biotechnology companies are major end users and drivers, using precision medicine in drug discovery, development, companion diagnostic co-development, and clinical trials, and academic and research institutes advance research and biomarker discovery. Nonetheless, the concentration of clinical delivery of precision medicine in hospitals and clinics secures the leadership of this segment across the forecast period, with laboratories and pharmaceutical companies growing in importance.
Precision Medicine Market Region Analysis
North America accounted for 48% of the global Precision Medicine market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare and genomic infrastructure, rapid adoption of molecular profiling and targeted therapy, strong research and investment, and the concentration of leading technology, diagnostic, and pharmaceutical companies. The United States leads on the strength of early and broad adoption of next-generation sequencing, companion diagnostics, and liquid biopsy, a large oncology and chronic disease burden, major genomics initiatives, and the presence of leading players including Illumina, Thermo Fisher Scientific, Roche through Foundation Medicine, Guardant Health, and Tempus AI, alongside major pharmaceutical developers of targeted therapies. The regulatory environment is well established, with the Food and Drug Administration providing pathways for targeted therapies and companion diagnostics and a track record of co-approvals. Reimbursement for molecular profiling has expanded, and strong research infrastructure, data capabilities, and investment further reinforce the market. This combination of infrastructure, adoption, and innovation reinforces North America's leadership in the global market.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Precision Medicine market. The region's elevated CAGR is driven by large populations, a rising burden of cancer and chronic disease, expanding healthcare access, growing genomic infrastructure, and increasing investment across China, Japan, India, South Korea, and Southeast Asia. Rising cancer incidence and increasing adoption of molecular profiling and targeted therapy are expanding demand, and growing healthcare investment and insurance coverage are improving access to precision diagnostics and therapies. China, in particular, is investing heavily in genomics, sequencing, and precision medicine, with a rapidly growing domestic industry, and other countries are expanding genomic infrastructure and national initiatives. Both multinational and regional companies are expanding their presence. Government genomics and precision medicine programs further support growth. The combination of large populations, rising disease burden, expanding access, and growing genomic infrastructure and investment positions Asia-Pacific as the highest-growth region over the forecast period.
Precision Medicine Market Regional Commentary
North America
North America accounted for 48% of the global Precision Medicine market revenue in 2025. The United States dominates the region on the strength of advanced genomic infrastructure, broad adoption of molecular profiling and targeted therapy, major genomics initiatives, and the presence of leading technology, diagnostic, and pharmaceutical companies, while Canada contributes through its research and healthcare systems and Mexico expands access within its growing healthcare sector.
Europe
Europe represents the second-largest regional market, led by Germany, the United Kingdom, and France. Growth is supported by strong research, national genomics initiatives such as those in the United Kingdom, and the presence of major companies, while the European In Vitro Diagnostic Regulation shapes diagnostic requirements and market access across the region.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by large populations, a rising burden of cancer and chronic disease, expanding healthcare access, and growing genomic infrastructure and investment across China, Japan, India, South Korea, and Southeast Asia. China's rapidly growing genomics industry and national initiatives are broadening capability and access.
Rest of World
The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. A rising burden of cancer and chronic disease, growing genomic infrastructure, national precision medicine initiatives in some countries, and expanding access are broadening adoption, while investment in genomics supports growth.
Precision Medicine Market Competitive Landscape
The Precision Medicine market is classified as Fragmented. A broad ecosystem of sequencing and technology companies, diagnostic companies, and pharmaceutical developers competes across the precision medicine value chain, led by technology and diagnostics leaders such as Illumina, Thermo Fisher Scientific, QIAGEN, Roche through Foundation Medicine, Guardant Health, and Tempus AI, and pharmaceutical leaders in targeted therapy such as Roche, Novartis, Pfizer, AstraZeneca, and Merck, alongside numerous specialized and regional players.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Fragmented, spanning sequencing and technology companies, diagnostic and data companies, and pharmaceutical developers of targeted therapies.
- Leading players: Illumina, Thermo Fisher Scientific, QIAGEN, Roche through Foundation Medicine, Guardant Health, and Tempus AI lead in technologies and diagnostics, while Roche, Novartis, Pfizer, AstraZeneca, and Merck lead in targeted therapies.
- Geographic reach: Leaders operate global commercial, laboratory, and research networks, with strong positions across North America, Europe, and Asia-Pacific.
- Product portfolio strength: Players hold portfolios spanning sequencing platforms, companion diagnostics, bioinformatics and data platforms, and targeted therapeutics.
- Pipeline strength: Deep pipelines in next-generation sequencing, liquid biopsy, companion diagnostics, artificial intelligence platforms, and targeted therapies.
- Strategic partnerships: Extensive drug-diagnostic co-development and pharma-technology data alliances shape the competitive landscape.
- M&A activity: Significant consolidation and acquisitions continue across diagnostics, data, and targeted therapeutics.
- Data and technology capabilities: Large multimodal datasets, bioinformatics, and artificial intelligence are increasingly central competitive assets.
- Innovation focus: Comprehensive genomic profiling, liquid biopsy, artificial intelligence and multimodal data, companion diagnostics, and targeted and biomarker-guided therapies.
Precision Medicine Market Recent Developmental Activities
- In 2023 and 2024, the Food and Drug Administration approved additional targeted therapies with companion diagnostics, including next-generation sequencing-based and liquid biopsy companion diagnostics. Strategic significance: Expands biomarker-guided treatment and drives adoption of molecular profiling.
- In 2023 and 2024, Roche, through Foundation Medicine, expanded its comprehensive genomic profiling and companion diagnostic offerings across tissue and liquid biopsy. Strategic significance: Reinforces leadership in comprehensive genomic profiling and companion diagnostics.
- In 2023 and 2024, Guardant Health and Natera expanded blood-based comprehensive genomic profiling and minimal residual disease testing. Strategic significance: Advances liquid biopsy across profiling, monitoring, and recurrence detection.
- In 2024, Illumina completed the divestiture of GRAIL, refocusing on its core sequencing business. Strategic significance: Sharpens Illumina's focus on sequencing technology that underpins precision medicine.
- In 2024, Tempus AI became a publicly traded company and expanded its multimodal data and artificial intelligence platform for precision oncology and other areas. Strategic significance: Highlights the growing role of artificial intelligence and multimodal data in precision medicine.
- In 2023 and 2024, strategic alliances between pharmaceutical companies and technology and data companies expanded to accelerate precision drug discovery. Strategic significance: Speeds the identification of targets and patient subgroups and strengthens the precision medicine ecosystem.
- In 2023 and 2024, next-generation sequencing costs continued to fall, and throughput increased with new platforms, broadening access to genomic profiling. Strategic significance: Expands the affordability and adoption of molecular profiling.
- In 2023 and 2024, national and institutional genomics and precision medicine initiatives advanced in the United States, the United Kingdom, and other countries. Strategic significance: Builds genomic infrastructure, data, and clinical adoption.
- In 2023 and 2024, pharmacogenomics testing expanded to guide drug selection and dosing across therapeutic areas. Strategic significance: Extends precision medicine beyond oncology into broader prescribing.
- In 2023 and 2024, artificial intelligence and multimodal data platforms expanded for biomarker discovery, clinical decision support, and drug development. Strategic significance: Improves the efficiency and precision of diagnosis, treatment, and research.
- In 2023 and 2024, comprehensive genomic profiling and companion diagnostics expanded beyond oncology into other therapeutic areas. Strategic significance: Broadens the applications and addressable market of precision medicine.
- In 2023 and 2024, the European In Vitro Diagnostic Regulation continued to reshape requirements and market access for diagnostics and companion diagnostics in Europe. Strategic significance: Raises compliance requirements and influences portfolio and market-entry strategies.
Precision Medicine Market Segmentation
- Precision Medicine Market by Technology
- Genomics and Next-Generation Sequencing
- Bioinformatics and Data Analytics
- Companion Diagnostics
- Pharmacogenomics
- Drug Discovery and Development
- Others
- Precision Medicine Market by Application
- Oncology
- Neurology
- Immunology
- Infectious Diseases
- Cardiovascular
- Respiratory
- Others
- Precision Medicine Market by End-User
- Hospitals and Clinics
- Diagnostic and Clinical Laboratories
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
Precision Medicine Market Assessment by Geography
- North America Precision Medicine Market Assessment
- United States Precision Medicine Market Size in USD million (2023-2034)
- Canada Precision Medicine Market Size in USD million (2023-2034)
- Mexico Precision Medicine Market Size in USD million (2023-2034)
- Europe Precision Medicine Market Assessment
- Germany Precision Medicine Market Size in USD million (2023-2034)
- United Kingdom Precision Medicine Market Size in USD million (2023-2034)
- France Precision Medicine Market Size in USD million (2023-2034)
- Italy Precision Medicine Market Size in USD million (2023-2034)
- Spain Precision Medicine Market Size in USD million (2023-2034)
- Rest of Europe Precision Medicine Market Size in USD million (2023-2034)
- Asia-Pacific Precision Medicine Market Assessment
- China Precision Medicine Market Size in USD million (2023-2034)
- Japan Precision Medicine Market Size in USD million (2023-2034)
- India Precision Medicine Market Size in USD million (2023-2034)
- Australia Precision Medicine Market Size in USD million (2023-2034)
- South Korea Precision Medicine Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Precision Medicine Market Size in USD million (2023-2034)
- Rest of the World (RoW) Precision Medicine Market Assessment
- Middle East Precision Medicine Market Size in USD million (2023-2034)
- Africa Precision Medicine Market Size in USD million (2023-2034)
- South America Precision Medicine Market Size in USD million (2023-2034)
Precision Medicine Market Recent Industry Trends and Milestones (2023-2026):
|
Category |
Key Developments |
|
Precision Medicine Market Product Approval |
The FDA approved additional targeted therapies with companion diagnostics, including NGS-based and liquid biopsy companion diagnostics; Roche through Foundation Medicine and Guardant Health expanded approved profiling; the European In Vitro Diagnostic Regulation continued to shape diagnostic requirements. |
|
Precision Medicine Market Product Expansion |
Roche through Foundation Medicine expanded comprehensive genomic profiling; Guardant Health and Natera expanded liquid biopsy and minimal residual disease testing; Illumina and Thermo Fisher advanced sequencing platforms; Tempus AI expanded its multimodal data and AI platform; pharmacogenomics testing expanded. |
|
Precision Medicine Market Product Investment |
Illumina divested GRAIL to refocus on sequencing (2024); Tempus AI became publicly traded (2024); pharmaceutical companies formed data and AI alliances to accelerate precision drug discovery; companies invested in liquid biopsy, AI platforms, and companion diagnostics; genomics initiatives expanded. |
|
Precision Medicine Market Company Strategy |
Illumina, Inc. and Thermo Fisher Scientific Inc.: Sequencing platforms. F. Hoffmann-La Roche Ltd and QIAGEN N.V.: Comprehensive genomic profiling and companion diagnostics. Guardant Health, Inc. and Tempus AI, Inc.: Liquid biopsy and AI-driven data. Novartis AG, Pfizer Inc., AstraZeneca plc, and Merck & Co., Inc.: Targeted and biomarker-guided therapies. |
|
Precision Medicine Market Emerging Technologies |
Comprehensive genomic profiling and next-generation sequencing; liquid biopsy for profiling, monitoring, and minimal residual disease; artificial intelligence and multimodal data platforms for discovery and clinical decision support; companion diagnostics; pharmacogenomics; and targeted and biomarker-guided therapies. |
Precision Medicine Market Startup Funding and Investment Trends
Investment in the precision medicine ecosystem has concentrated on artificial intelligence-driven drug discovery and diagnostics, multiomic data platforms, and blood-based molecular testing. The following companies illustrate recent activity and technology focus.
|
Company |
Total Funding |
Funding Stage |
Main Product |
Core Technology |
|
Owkin, Inc. |
Venture funding |
Growth-stage venture |
AI drug discovery and diagnostics platform |
Artificial intelligence and multimodal data for precision drug discovery and diagnostics |
|
Freenome Holdings, Inc. |
Venture funding |
Growth-stage venture |
Blood-based cancer detection tests |
Multi-omics blood-based early detection and machine learning |
|
 Request to unlock the report on the @ Precision Medicine Market Insights  | ||||
Owkin is developing artificial intelligence and multimodal data platforms for precision drug discovery, diagnostics, and clinical decision-making, while Freenome develops multiomics blood-based tests for early cancer detection using machine learning. Additional capital continues to flow toward artificial intelligence-driven discovery and diagnostics, multiomic data platforms, liquid biopsy, and blood-based molecular testing, reflecting conviction that data-driven, minimally invasive, and personalized approaches are the next source of competitive advantage. Collectively, these efforts signal sustained investment in advancing the precision, efficiency, and reach of diagnosis and treatment and in addressing diseases with high unmet need.
Key Takeaways from the Precision Medicine Market Report Study
- Market size analysis for the current precision medicine market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global precision medicine market.
- Various opportunities available for competitors in the precision medicine market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current precision medicine market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for precision medicine market growth in the future?
Target audience that can benefit from this precision medicine market report study
- Precision Medicine product and service providers
- Research organizations and consulting companies
- Precision Medicine-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in precision medicine technologies and diagnostics
- Various end-users who want to know more about the precision medicine market and the latest technological developments in the precision medicine market.
Frequently Asked Questions
Q1. What is the growth rate of the Precision Medicine market?
The Precision Medicine market is projected to expand at a CAGR of 11.8% during the forecast period of 2026-2034.
Q2. What is the market size of the Precision Medicine market?
The Precision Medicine market is estimated at USD 110 billion in 2025 and is projected to reach USD 300 billion by 2034.
Q3. Which region dominates the Precision Medicine market?
North America dominated the Precision Medicine market with a 48% share of global revenue in 2025, supported by advanced genomic infrastructure, broad adoption of molecular profiling and targeted therapy, major genomics initiatives, supportive FDA pathways, and the presence of leading technology, diagnostic, and pharmaceutical companies. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Precision Medicine market?
The principal drivers are the rising burden of cancer and chronic disease; the falling cost and expanding use of genomic sequencing; the rapid growth of targeted therapies and companion diagnostics; and the application of artificial intelligence and big data to drug discovery and clinical care, reinforced by the growth of liquid biopsy and government and institutional genomics initiatives.
Q5. Who are the major players in the Precision Medicine market?
The major Precision Medicine companies in the market include F. Hoffmann-La Roche Ltd, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Novartis AG, Pfizer Inc., AstraZeneca plc, Merck & Co., Inc., Guardant Health, Inc., and Tempus AI, Inc., among other active companies profiled in the Competitive Landscape section. Illumina, Thermo Fisher, Roche through Foundation Medicine, Guardant Health, and Tempus AI lead in technologies and diagnostics, while major pharmaceutical companies lead in targeted therapies.



